SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind received FDA approval for Afrezza® in children and adolescents…

MannKind · PRESS-RELEASE filed May 29, 2026 at 14:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 29, 2026 at 14:00 ET

MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient population for the company's inhaled insulin product, a significant label expansion for a single-product biotech with a $1.1B market cap. The stock has a history of high volatility on news events.

  • FDA approved Afrezza for use in children and adolescents aged 6+ with diabetes
  • This is a label expansion for MannKind's sole marketed product, Afrezza
  • Company has a $1.1B market cap, early-stage biotech dynamics apply

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access